Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show great promise for treatment of diseases from genetic disorders to cancer. Accordingly, there is an unprecedented need for high titer and large-scale viral vector manufacturing processes to support the growing number of researchers developing biotherapeutics for immunotherapy.

Download this Special Report, highlighting:

• Evolutions of gene therapy manufacturing
• Improvements to GMP raw-material sourcing.
• Role of transfection reagents like VirusGEN® GMP as a turnkey element to optimize virus production.
• Transfection reagent quality and regulatory considerations.

Fill out the form below to read the complete report now.